Skip to main content

Latest News

all news
all events
October 31, 2024

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer

Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer.  He has...
+
September 09, 2024

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3

NLRP3 is a promising target with a well-validated role in various inflammatory disease Secarna has shown the potential of the company’s ASOs to effectively and specifically suppress NLRP3 and IL-1β release In a CAPS mouse model, Secarna demonstrated prolonged survival and a significant reduct...
+
September 04, 2024

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Scientific Advisory Board (SAB) to offer expert guidance and direction for the development of lead compound SECN-15 and the Company’s oncology pipeline Dr. Alexander M.M. Eggermont convened SAB as of July 1, 2024 together with Prof. Dr. Alfred Zippelius, who has been an advisor to Secarna sinc...
+
July 22, 2024

Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs

Antisense oligonucleotides (ASOs) possess the potential to cause considerable immune stimulation via toll-like receptor 9 (TLR9) Specific chemical modifications of ASOs, such as LNA or methylation, may mitigate – but in certain cases also enhance – immune reactions triggered by ASOs New publi...
+
May 28, 2024

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Partnership expands spectrum of Secarna’s capabilities for the development of targeted ASOs beyond antibodies and sugar molecules New platform capabilities extend the reach of Secarna’s antisense approaches, potentially offering new treatment options for a wider range of diseases Martinsrie...
+
March 20, 2024

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Dallas and Martinsried, March 20, 2024 - Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for...
+
November 03, 2023

Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1

Neuropilin-1 (NRP1), implicated in various pro-tumorigenic processes, is a promising therapeutic target for cancer treatment Secarna designed LNA-modified NRP1 specific antisense oligonucleotides (ASOs) that effectively knockdown target gene expression, resulting in increased survival and red...
+
October 25, 2023

Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

Comprehensive data sets presented in two poster presentations at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) Secarna investigated the immunostimulatory potential of LNA-modified antisense oligonucleotides (ASOs), a potential factor of undesired side effects of tre...
+
October 17, 2023

Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society

Munich/Martinsried, Germany, October 17, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via it...
+
July 06, 2023

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases

Secarna’s LNAplus™ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory diseases Cryopyrin-associated periodic syndrome (CAPS) is a group of rare inherited autoinflammatory diseases driven by overactive NLRP3, resulting in...
+
June 05, 2023

Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expression

Compelling in vivo and in vitro data published in peer-reviewed Journal for ImmunoTherapy of Cancer (JITC)  Secarna’s LNAplus™-based ASOs effectively stimulate TLR9 signaling, an important innate immune pathway, and simultaneously suppress PD-L1 expression, a clinically validated imm...
+
March 27, 2023

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases

Munich/Martinsried, Germany, March 27, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, and Sci...
+
May 31, 2022

First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform

First antisense oligonucleotide (ASO) derived from Secarna’s LNAplus™ technology platform to enter the clinic after a series of successful pre-clinical proof-of-concept programs in various indications Lipigon received approval from the Swedish Medical Products Agency to commence a phase I clin...
+
April 12, 2022

Secarna Pharmaceuticals’ strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

The programme designation is based on an antisense-based approach which triggers a US$ 16 M payment to Evotec by Bristol Myers Squibb Evotec sources LNAplusTM antisense technology through a strategic partnership with Secarna Pharmaceuticals Munich/Martinsried, Germany, April 12, 2022 – Seca...
+
February 22, 2022

Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

First development program for which Denali exercised an option under the ongoing and recently expanded collaboration Secarna’s LNAplusTM antisense oligonucleotides (ASOs) combined with Denali’s Oligonucleotide Transport Vehicle (OTV) technology provide potential for novel therapies in the area...
+
November 10, 2021

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T cell therapies

Secarna’s LNAplus™ ASOs have the potential to optimize personalized T cell therapies being developed by Achilles Secarna’s industry-leading antisense oligonucleotide (ASO) platform LNAplus™ enables discovery and research of ASOs against undisclosed targets in the area of immune oncology Mun...
+
October 26, 2021

Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases

Companies broaden use of Secarna’s industry-leading ASO discovery and development platform LNAplus™ and Denali’s blood-brain barrier Transport Vehicle (TV) technology Multiple new programs across a range of indications added to the partnership entered into in 2020 Munich/Martinsried, German...
+
October 25, 2021

Secarna Pharmaceuticals has initiated a transnational scientific consortium to identify new biomarkers for personalized cancer immunotherapy with ASOs

Secarna has joined forces with the Latvian Institute of Organic Synthesis, the leading drug discovery and development center in the Baltics, the Institute of Bioinformatics (Medical University of Innsbruck) and Innoplexus AG, the leading Artificial Intelligence (AI) platform for drug discovery ...
+
October 05, 2021

Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus™-based ASOs to effectively treat diabetic kidney disease

Compelling in vivo and in vitro data published in peer-reviewed Journal of the American Society of Nephrology Secarna’s LNAplusTM-based ASOs effectively and specifically target cell death-promoting transcription factor C/EBP homologous protein (CHOP), a mediator of diabetes-induced stress cond...
+
September 02, 2021

Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery

In addition to the successful ongoing collaboration on a co-owned LNAplusTM ASO pipeline, Secarna and Evotec now also start to jointly work on third-party discovery, research and development programs The two companies will leverage Secarna’s industry-leading antisense oligonucleotide expertise...
+
August 05, 2021

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

Secarna pioneers antisense research by characterization of multi-specific antisense oligonucleotides to identify factors that determine target gene knockdown Top factors identified to have an impact on ASOs’ activity include abundance of the target transcript, length of the transcript, binding...
+
February 05, 2021

Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies

Antisense oligonucleotide (ASO)-based therapeutics have evolved as a fully accepted therapeutic modality, next to small molecules and therapeutic antibodies During the drug candidate selection process, RNA-sequencing combined with bioinformatic screens could provide a valuable tool to assess A...
+
February 05, 2021

Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director

Munich/Martinsried, Germany, February 04, 2021 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via i...
+
December 11, 2020

Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections

Secarna to develop LNAplusTM-based antisense oligonucleotides which specifically suppress the expression of a certain host factor essential to the SARS-CoV-2 viral infection cycle Targeting host factors avoids risk of virus evading treatment due to mutation – a major issue when directly target...
+
December 11, 2020

Secarna Pharmaceuticals and Evotec form strategic partnership in the field of antisense therapy

Comprehensive long-term platform agreement for the development of novel antisense oligonucleotide therapeutics across a broad range of targets and indications Secarna and Evotec share discovery and development responsibilities building co-owned industry-leading LNAplusTM-based antisense pipeli...
+
December 11, 2020

Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases

Companies will leverage Secarna’s industry-leading antisense oligonucleotide (ASO) discovery and development platform LNAplusTM and Denali’s blood-brain barrier technology to discover and develop novel therapeutics for neurodegenerative diseases with high unmet medical need 
 Financial terms w...
+
October 13, 2020

Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals’ LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

Secarna’s partner Lipigon has selected an LNAplus™ ASO candidate targeting ANGPTL4, called Lipisense, which has shown unique efficacy in reducing lipid triglycerides in experimental disease models and is now entering pre-clinical safety development High levels of plasma lipids triglycerides ar...
+
March 27, 2018

BIO-Europe Spring® 2018 / Secarna MD Jonas Renz on standing out in a crowd

+